0
No hay productos en el carro de la compra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > B7-H3

B7-H3

Brief Information

Name:CD276 antigen
Target Synonym:B7 homolog 3,PSEC0249,UNQ309/PRO352,B7-H3,CD276 antigen,B7H3,CD276,CD276 Molecule,Costimulatory Molecule,4Ig-B7-H3,B7RP-2
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:45
Lastest Research Phase:NDA/BLA

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

B73-H52E2-Cell-based assay
 B7-H3 CELL

Human B7-H3, His Tag (Cat. No. B73-H52E2) inhibits Anti-CD3-induced proliferation of PBMC. The EC50 for this effect is 2.24-3.36 μg/mL (Routinely tested).

B73-H52E2-BLI
 B7-H3 BLI

Loaded Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 on Protein A Biosensor, can bind Human B7-H3 Protein, His Tag (Cat. No. B73-H52E2) with an affinity constant of 479 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

B73-H82E6-ELISA
 B7-H3 ELISA

Immobilized Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 at 2 μg/mL (100 μL/well) can bind Biotinylated Human B7-H3 Protein, Avitag,His Tag (Cat. No. B73-H82E6) with a linear range of 5-39 ng/mL (QC tested).

Synonym Name

B7-H3,CD276,B7 homolog 3

Background

B7 homolog 3 (B7-H3), a member of the immunoglobulin superfamily, is also known CD276, which contains two Ig-like C2-type (immunoglobulin-like) domains and two Ig-like V-type (immunoglobulin-like) domains. B7-H3 may participate in the regulation of T-cell-mediated immune response. B7-H3 also plays a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. Furthermore, B7-H3 is involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. It could also play a key role in providing the placenta and fetus with a suitable immunological environment throughout pregnancy.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Ifinatamab deruxtecan I-DXd; MK-2400; DS-7300a; DS-7300; MABX-9001a Phase 3 Clinical Daiichi Sankyo Co Ltd Solid tumours; Esophageal Neoplasms; Small Cell Lung Carcinoma; Esophageal Squamous Cell Carcinoma; Lung Neoplasms Details
YL-201 YL-201; YL201 Phase 3 Clinical MediLink Therapeutics Co Ltd Solid tumours; Small Cell Lung Carcinoma; Prostatic Neoplasms, Castration-Resistant; Nasopharyngeal Carcinoma Details
HS-20093 GSK-5764227; GSK’227; HS-20093; HS20093; GSK5764227 Phase 3 Clinical Shanghai Hansoh Biomedical Co Ltd Solid tumours; Ovarian Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Soft Tissue Neoplasms; Sarcoma; Osteosarcoma; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
B7-H3 CAR-T cell therapy (Boyuan Runsheng Pharma) Phase 2 Clinical Boyuan Runsheng Pharma (Hangzhou) Co Ltd Solid tumours; Glioblastoma Details
Obrindatamab MGD-009; B7-H3 x CD3 Phase 2 Clinical Macrogenics Inc Sarcoma, Synovial; Carcinoma, Non-Small-Cell Lung; Melanoma; Thyroid Neoplasms; Breast Neoplasms; Neurofibrosarcoma; Prostatic Neoplasms; Neuroblastoma; Sarcoma; Ovarian Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Colonic Neoplasms; Wilms Tumor; Pancreatic Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma Details
Vobramitamab duocarmazine MGC-018 Phase 2 Clinical Macrogenics Inc Solid tumours; Anus Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Hormone-Resistant Prostate Neoplasms; Carcinoma, Ovarian Epithelial; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Small Cell; Laryngeal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
TAK-280 MVC-280; TAK-280 Phase 2 Clinical Maverick Therapeutics Inc Solid tumours; Neoplasms; Neoplasm Metastasis Details
DB-1419 DB-1419 Phase 2 Clinical Duality Biologics (Suzhou) Co Ltd Solid tumours Details
IBI129 IBI-129; IBI129 Phase 2 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours Details
7MW3711 7-MW-3711; 7MW3711 Phase 2 Clinical Mabwell (Shanghai) Bioscience Co Ltd Solid tumours; Neoplasms Details
IBI334 IBI334; IBI-334 Phase 2 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours Details
MHB088C MHB-088C Phase 2 Clinical Minghui Pharmaceutical Pty Ltd Solid tumours Details
DB-1311 DB-1311; BNT-324 Phase 2 Clinical Duality Biologics (Suzhou) Co Ltd Solid tumours; Neoplasm Metastasis Details
IBB-0979 IBB0979; IBB-0979 Phase 2 Clinical SunHo (China) BioPharmaceutical Co Ltd Solid tumours; Neoplasms Details
ILB-3101 ILB-3101 Phase 2 Clinical Innolake Biopharm (Hangzhou) Co Ltd Solid tumours; Neoplasms; Leukemia, Myeloid, Acute Details
Fully Human B7H3 CAR-T Cells Therapy fhB7H3.CAR-Ts Phase 2 Clinical The Affiliated Hospital Of Xuzhou Medical University Ovarian Neoplasms; Carcinoma, Hepatocellular Details
CD-276-targeted Chimeric Antigen Receptor T Cell Therapy CD276 CAR-T Phase 2 Clinical Shenzhen University General Hospital Pancreatic Neoplasms Details
Enoblituzumab MGA-271; TJ271 Phase 2 Clinical Macrogenics Inc Wilms Tumor; Melanoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Urethral Neoplasms; Sarcoma, Ewing; Osteosarcoma; Prostatic Neoplasms; Neuroblastoma; Urinary Bladder Neoplasms; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Abdominal Neoplasms; Carcinoma, Renal Cell; Desmoplastic Small Round Cell Tumor; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms; Rhabdomyosarcoma; Solid tumours Details
SC-CAR4BRAIN Phase 1 Clinical Seattle Children'S Hospital Sarcoma, Synovial; Neoplasms, Germ Cell and Embryonal; Diffuse Intrinsic Pontine Glioma; Sarcoma, Clear Cell; Osteosarcoma; Retinoblastoma; Neuroblastoma; Neurofibrosarcoma; Sarcoma, Ewing; Sarcoma; Solid tumours; Central Nervous System Neoplasms; Wilms Tumor; Carcinoma; Rhabdoid Tumor; Hepatoblastoma; Diffuse midline glioma; Desmoplastic Small Round Cell Tumor; Rhabdomyosarcoma Details
124I-omburtamab 124I-8H9; 124I-8H9-(B7-H3) Phase 1 Clinical Memorial Sloan Kettering Cancer Center, Y-Mabs Therapeutics Inc Brain Neoplasms; Glioma Details
Mirzotamab clezutoclax ABBV-155 Phase 1 Clinical Abbvie Inc Solid tumours Details
second generation anti-CD276 CAR T-cell therapy (Seattle Children's Hospital/Cureworks) Phase 1 Clinical Seattle Children'S Hospital Rhabdomyosarcoma; Solid tumours; Hepatoblastoma; Neoplasms; Wilms Tumor; Neuroblastoma; Osteosarcoma; Retinoblastoma; Sarcoma; Sarcoma, Ewing; Carcinoma, Embryonal; Melanoma Details
BCB-276 BRAINCHILD-03; SCRI-CARB7H3 Phase 1 Clinical Seattle Children'S Hospital, BrainChild Bio Inc Sarcoma; Melanoma; Neoplasms, Germ Cell and Embryonal; Choroid Plexus Neoplasms; Glioma; Neuroectodermal Tumors, Primitive; Diffuse Intrinsic Pontine Glioma; Neuroblastoma; Retinoblastoma; Neurofibrosarcoma; Sarcoma, Ewing; Sarcoma, Clear Cell; Osteosarcoma; Teratoma; Sarcoma, Synovial; Central Nervous System Neoplasms; Wilms Tumor; Rhabdoid Tumor; Hepatoblastoma; Desmoplastic Small Round Cell Tumor; Carcinoma; Diffuse midline glioma; Rhabdomyosarcoma; Ependymoma; Medulloblastoma; Solid tumours Details
CC-3 CC-3 Phase 1 Clinical Eberhard Karls University Of Tubingen, Germany Colorectal Neoplasms; Gastrointestinal Neoplasms Details
KT-095 KT-095 Phase 1 Clinical Nanjing Kati Medical Technology Co Ltd Solid tumours Details
EX-105 EX-105; EX105 Phase 1 Clinical Guangzhou Excelmab Inc Solid tumours Details
GTB-5550 GTB-5550; B7H3 TriKE™; cam1615B7H3; GTB-5550 TriKE™ Phase 1 Clinical University Of Minnesota Solid tumours Details
WL276 CAR-T Cell Therapy(Immunochina Medical Science & Technology) Phase 1 Clinical Beijing Immunochina Medical Science & Technology Co Ltd Glioblastoma Details
CAR.B7-H3 T cells (Unc Lineberger Comprehensive Cancer Center) Phase 1 Clinical Unc Lineberger Comprehensive Cancer Center Glioblastoma Details
[68Ga] B7H3 Affibody-BCH(Beijing Cancer Hospital) Phase 1 Clinical Beijing Cancer Hospital Neoplasms Details
BGB-C354 BGB-C354 Phase 1 Clinical BeOne Medicines Ltd Solid tumours; Lung Neoplasms; Gastrointestinal Neoplasms Details
IBI-3001 IBI-3001; IBI3001 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours Details
MGC-026 MGC026; MGC-026 Phase 1 Clinical Macrogenics Inc Prostatic Neoplasms, Castration-Resistant; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms Details
Loco-regional B7H3 IL-7Ra CAR T Cell therapy(Chulalongkorn University) Phase 1 Clinical Chulalongkorn University, King Chulalongkorn Memorial Hospital Solid tumours; Neoplasms; Brain Neoplasms; Diffuse Intrinsic Pontine Glioma Details
Autologous CAR-T Cells Targeting B7-H3(Unc Lineberger Comprehensive Cancer Center) Phase 1 Clinical Bellicum Pharmaceuticals Inc, Unc Lineberger Comprehensive Cancer Center Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms Details
MT-027 MT-027 Phase 1 Clinical T-Maximum Pharmaceutical (Suzhou) Co Ltd Solid tumours; Central Nervous System Neoplasms; Mesothelioma; Brain Neoplasms; Glioma; Nervous System Neoplasms; Pleural Neoplasms; Pleural Effusion, Malignant Details
UTAA-06 UTAA-06; UTAA06 Phase 1 Clinical Persongen Biotherapeutics (Suzhou) Co Ltd Solid tumours; Leukemia, Myeloid, Acute Details
B7-H3 CAR T-cell therapy(Stanford University) B7-H3CART Phase 1 Clinical Stanford University Ovarian Neoplasms; Neuroblastoma; Osteosarcoma; Sarcoma; Nervous System Diseases Details
TX-103 TX-103 Phase 1 Clinical Fuzhou Tcelltech Biological Science and Technology Co Ltd Solid tumours; Glioma Details
EGFR/B7H3 CAR-T EGFR/B7H3 CAR-T Phase 1 Clinical Second Affiliated Hospital Of Guangzhou Medical University Triple Negative Breast Neoplasms; Lung Neoplasms Details
B7-H3-targeting CAR-T cell therapy Phase 1 Clinical Beijing Tiantan Hospital, Capital Medical University Glioblastoma Details
BAT-8009 BAT8009; BAT-8009 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours Details
TAA-06 TAA06-UCAR-γδT; TAA-06 Phase 1 Clinical Persongen Biotherapeutics (Suzhou) Co Ltd Solid tumours; Neuroblastoma; Colorectal Neoplasms; Lung Neoplasms; Melanoma Details
XmAb-808 XmAb808 Phase 1 Clinical Xencor Inc Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Prostatic Neoplasms, Castration-Resistant; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Anti-CD276 CAR T-cell therapy (Persongen ) Phase 1 Clinical Persongen Biotherapeutics (Suzhou) Co Ltd Stomach Neoplasms; Osteosarcoma; Neuroblastoma; Lung Neoplasms Details
TX-103-CAR-T TX-103-CAR-T Clinical Union Hospital Affiliated To Fujian Medical University Head and Neck Neoplasms; Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Glioma Details
Allogenic B7H3-targeting CAR-γδT Cell Therapy QH104 Cell; QH-104 Cell Clinical Suzhou Dushu Lake Hospital (Dushu Lake Hospital Affiliated To Soochow University) Glioblastoma; Glioma Details

This web search service is supported by Google Inc.

totop
Email
Correo electrónico
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Dejar un mensaje